FDA approves DAYBUE STIX (trofinetide), powder formulation
Filed with ASX · · 3 pages · English
Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) today announced that its partner, Acadia Pharmaceuticals (Nasdaq: ACAD), has received US Food and Drug Administration (FDA) approval of DAYBUE® STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation of trofinetide for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. The
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Record DAYBUE net sales of US$101.1 million in Q3 2025
- Fast Track granted by FDA for NNZ-2591 in Phelan-McDermid
- Half Yearly Report and Accounts
- First site initiated for Neuren's PMS Phase 3 trial
- Neuren adds SYNGAP1-related disorder to NNZ-2591 pipeline
Later from Neuren Pharmaceuticals
- DAYBUE net sales projected to reach approx US$700m in 2028
- Response to ASX Aware Letter
- Acadia provides update on EU regulatory submission
- Trading Halt
- Neuren receives US FDA meeting feeback for HIE and PTHS
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals